» Articles » PMID: 24807559

Expression of the Iron Hormone Hepcidin Distinguishes Different Types of Anemia in African Children

Abstract

Childhood anemia is a major global health problem resulting from multiple causes. Iron supplementation addresses iron deficiency anemia but is undesirable for other types of anemia and may exacerbate infections. The peptide hormone hepcidin governs iron absorption; hepcidin transcription is mediated by iron, inflammation, and erythropoietic signals. However, the behavior of hepcidin in populations where anemia is prevalent is not well established. We show that hepcidin measurements in 1313 African children from The Gambia and Tanzania (samples taken in 2001 and 2008, respectively) could be used to identify iron deficiency anemia. A retrospective secondary analysis of published data from 25 Gambian children with either postmalarial or nonmalarial anemia demonstrated that hepcidin measurements identified individuals who incorporated >20% oral iron into their erythrocytes. Modeling showed that this sensitivity of hepcidin expression at the population level could potentially enable simple groupings of individuals with anemia into iron-responsive and non-iron-responsive subtypes and hence could guide iron supplementation for those who would most benefit.

Citing Articles

Serum hepcidin recalibrated values in Mexican schoolchildren by demographic characteristics, nutritional and infection/inflammation status.

Mendoza E, Duque X, Reyes-Maldonado E, Hernandez-Franco J, Martinez-Andrade G, Vilchis-Gil J Ann Hematol. 2024; 103(10):3979-3986.

PMID: 39039174 DOI: 10.1007/s00277-024-05889-4.


The Role of Hepcidin and an Oral Iron Absorption Test in Identifying the Root Cause of Iron-Restricted Anemia (Enter-Iron).

Loveikyte R, van den Berg Y, van der Meulen-de Jong A, Vlasveld L Acta Haematol. 2023; 147(4):402-412.

PMID: 37972576 PMC: 11296559. DOI: 10.1159/000535275.


Protocol for a randomised, multicentre, four-arm, double-blinded, placebo-controlled trial to assess the benefits and safety of iron supplementation with malaria chemoprevention to children in Malawi: IRMA trial.

Mwangi M, Mzembe G, Ngwira C, Vokhiwa M, Kapulula M, Larson L BMJ Open. 2023; 13(10):e069011.

PMID: 37832986 PMC: 10583080. DOI: 10.1136/bmjopen-2022-069011.


A novel nano-iron supplement versus standard treatment for iron deficiency anaemia in children 6-35 months (IHAT-GUT trial): a double-blind, randomised, placebo-controlled non-inferiority phase II trial in The Gambia.

Mohammed N, Wason J, Mendy T, Nass S, Ofordile O, Camara F EClinicalMedicine. 2023; 56:101853.

PMID: 36880049 PMC: 9985047. DOI: 10.1016/j.eclinm.2023.101853.


Ferric carboxymaltose and SARS-CoV-2 vaccination-induced immunogenicity in kidney transplant recipients with iron deficiency: The COVAC-EFFECT randomized controlled trial.

Vinke J, Altulea D, Eisenga M, Jagersma R, Niekolaas T, van Baarle D Front Immunol. 2023; 13:1017178.

PMID: 36618359 PMC: 9822258. DOI: 10.3389/fimmu.2022.1017178.